Epilepsy News and Research

Latest Epilepsy News and Research

Mutations in STRAD-alpha gene can cause PMSE syndrome in Amish children: Penn researchers

So often the rare informs the common. Penn researchers investigating a regulatory protein involved in a rare genetic disease have shown that it may be related to epileptic and autistic symptoms in other more common neurological disorders.

12 May 2010

Iowa researcher uses new technique to verify brain's master switch

The protein that has long been suspected by scientists of being the master switch allowing brains to function has now been verified by an Iowa State University researcher.

10 May 2010

Icagen reports revenues of $1.5M, net loss of $3.2M for first-quarter 2010

Icagen, Inc. reported today its financial results and operational highlights for the first quarter ended March 31, 2010. For the first quarter of 2010, the Company reported revenues of $1.5 million and a net loss of $3.2 million. As of March 31, 2010, the Company's cash and cash equivalents totaled $14.3 million.

7 May 2010

Survey reveals low awareness of postherpetic neuralgia amongst Americans

The American Pain Foundation (APF) announced today at the American Pain Society (APS) Annual Meeting the results of a national survey that showed postherpetic neuralgia (PHN), also known as after-shingles pain, continues to be a condition with low awareness amongst Americans, demonstrating a need for health care provider (HCP) intervention.

7 May 2010

Keryx Biopharmaceuticals commences Phase 3 registration program for Zerenex

Keryx Biopharmaceuticals, Inc. announced today the initiation of its short-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

6 May 2010

SCOLR Pharma grants RedHill worldwide rights to market and sell CDT-based ondansetron

SCOLR Pharma, Inc. today announced that it has executed a Licensing Agreement with RedHill Biopharma Ltd. an Israeli corporation, (RedHill), granting RedHill the worldwide rights to market and sell ondansetron tablet formulations based on SCOLR's proprietary extended delivery technology (CDT). Ondansetron hydrochloride is the active ingredient in Zofran®, GlaxoSmithKline's drug to prevent chemotherapy and radiation related nausea and vomiting.

6 May 2010

Researchers analyze spine surgery patients' existing comorbdities in relationship to hospital stay, costs

It is estimated that between 75 and 85 percent of all Americans will suffer from low back pain and/or neck pain at some point in their lives. An estimated 12 million Americans suffer from degenerative disc disease, with over one million patients undergoing surgery each year. The cost of treating back pain is currently estimated at more than $100 billion annually in the U.S. Many patients with back pain have comorbidities that impact spine surgery.

5 May 2010

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

Anavex Life Sciences Corp. is pleased to report promising results from animal studies with ANAVEX 2-73, the company's lead compound for the treatment and modification of Alzheimer's disease.

5 May 2010

Researchers explore role of ECoG measurement to improve brain mapping technology

Epilepsy and seizures affect nearly 3 million Americans of all ages, with 200,000 new cases of seizures and epilepsy occurring each year. Epilepsy surgery may be performed in patients who have seizures associated with structural brain abnormalities, such as benign brain tumors and cortical dysplasia, malformations of blood vessels, the genetic disorder tuberous sclerosis, and strokes.

4 May 2010

Researchers receive $250,000 to study inventive cell-transfer therapy to treat cortical dysplasia

University of Florida researchers will receive $250,000 to study an inventive cell-transfer therapy to treat cortical dysplasia, a condition where the brain develops abnormally before birth, causing severe epilepsy in children and adults.

4 May 2010

Sepracor issued FDA Complete Response Letter for STEDESA NDA

Sepracor Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA, or Agency) has issued a Complete Response Letter to Sepracor's New Drug Application (NDA) for its antiepileptic drug candidate, STEDESA™, which is the company's proposed trade name for eslicarbazepine acetate.

4 May 2010

Parents administering highly complex medication regimens require additional supports

Parents of children with chronic conditions make many mistakes when giving lifesaving medicines, according to a study being presented Monday, May 3 at the Pediatric Academic Societies (PAS) annual meeting in Vancouver, British Columbia, Canada.

3 May 2010

Elekta Neuromag tool to be highlighted at AANS 2010 Annual Meeting

At the 2010 American Association of Neurological Surgeons Annual Meeting, May 1-5 at the Pennsylvania Convention Center, Elekta will host a series of presentations highlighting Elekta Neuromag, a tool that measures and records brain activity using magnetoencephalography technology.

From Elekta 30 Apr 2010

Johnson & Johnson subsidiaries agree to pay over $81M to resolve Topamax illegal promotion allegations

American pharmaceutical manufacturers Ortho-McNeil Pharmaceutical LLC and Ortho-McNeil-Janssen Pharmaceuticals Inc., both subsidiaries of Johnson & Johnson, have agreed to pay more than $81 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Topamax, the Justice Department announced today.

30 Apr 2010

Natus Medical's revenue for first-quarter 2010 increased 47% to $49.2M

Natus Medical Incorporated today announced financial results for the three months ended March 31, 2010.

29 Apr 2010

Update on ICA-105665 clinical development plans for treatment of epilepsy and pain

Icagen, Inc. today provided an update on clinical development plans for ICA-105665, the Company's novel drug candidate for the treatment of epilepsy and pain.

28 Apr 2010

Natus Medical announces $50M revolving credit facility with Wells Fargo Bank

Natus Medical Incorporated today announced that it has entered into a $50 million revolving credit facility with Wells Fargo Bank, National Association. The credit facility, which matures on April 30, 2012, amends and restates the Company's existing $25 million credit facility that was scheduled to mature on April 30, 2010.

27 Apr 2010

Tel Aviv University researcher maps drug target to wipe pain away

In most cases of chronic pain -- lingering pain that never seems to go away after accidents or prolonged illnesses ― no pill exists to dull the hurt. Billions of dollars are lost every year in sick days taken to alleviate chronic pain, and as much money is spent by the healthcare system to diagnose what's wrong.

27 Apr 2010

Phase 2b clinical study initiated to evaluate GI safety of LT-NS001

Logical Therapeutics, Inc., a Waltham, Mass.-based biotechnology company announced today the initiation of a Phase 2b clinical study to evaluate the gastrointestinal safety of its investigational drug LT-NS001 (naproxen etemesil). The study will compare the cumulative rate of gastric ulcers vs. Naprosyn after 12 weeks of treatment.

27 Apr 2010

Catalyst Pharmaceutical Partners regains compliance for continued listing on The Nasdaq Capital Market

Catalyst Pharmaceutical Partners, Inc. announced today that it has received notice from The NASDAQ Stock Market confirming that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.

27 Apr 2010

Epilepsy News and Research

Latest Epilepsy News and Research

Mutations in STRAD-alpha gene can cause PMSE syndrome in Amish children: Penn researchers

Iowa researcher uses new technique to verify brain's master switch

Icagen reports revenues of $1.5M, net loss of $3.2M for first-quarter 2010

Survey reveals low awareness of postherpetic neuralgia amongst Americans

Keryx Biopharmaceuticals commences Phase 3 registration program for Zerenex

SCOLR Pharma grants RedHill worldwide rights to market and sell CDT-based ondansetron

Researchers analyze spine surgery patients' existing comorbdities in relationship to hospital stay, costs

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

Researchers explore role of ECoG measurement to improve brain mapping technology

Researchers receive $250,000 to study inventive cell-transfer therapy to treat cortical dysplasia

Sepracor issued FDA Complete Response Letter for STEDESA NDA

Parents administering highly complex medication regimens require additional supports

Elekta Neuromag tool to be highlighted at AANS 2010 Annual Meeting

Johnson & Johnson subsidiaries agree to pay over $81M to resolve Topamax illegal promotion allegations

Natus Medical's revenue for first-quarter 2010 increased 47% to $49.2M

Update on ICA-105665 clinical development plans for treatment of epilepsy and pain

Natus Medical announces $50M revolving credit facility with Wells Fargo Bank

Tel Aviv University researcher maps drug target to wipe pain away

Phase 2b clinical study initiated to evaluate GI safety of LT-NS001

Catalyst Pharmaceutical Partners regains compliance for continued listing on The Nasdaq Capital Market

Everything you need to know about epilepsy eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Epilepsy News and Research

Latest Epilepsy News and Research

Everything you need to know about epilepsy eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in